NCT03325361

Brief Summary

Anastomotic leakage (AL) is considered the commonest major complication after surgery for rectal cancer. Transanal tube drainage role in the prevention of AL is still debatable.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2017

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

October 24, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 30, 2017

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

October 30, 2017

Status Verified

October 1, 2017

Enrollment Period

2 months

First QC Date

October 24, 2017

Last Update Submit

October 24, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Anastomotic leakage

    Prevention

    30 days

Study Arms (2)

TD

EXPERIMENTAL
Other: Tube drain insertion

NTD

NO INTERVENTION

Interventions

A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.

TD

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Low or ultralow anterior resection with primary anastomosis for biopsy-proven primary rectal cancer

You may not qualify if:

  • No anastomosis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Policlinico Tor Vergata Hospital

Rome, RM, 00133, Italy

RECRUITING

MeSH Terms

Conditions

Rectal NeoplasmsAnastomotic Leak

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesIntestinal DiseasesRectal DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Pierpaolo Sileri, PhD

CONTACT

Mostafa Shalaby, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 24, 2017

First Posted

October 30, 2017

Study Start

October 1, 2017

Primary Completion

December 1, 2017

Study Completion

June 1, 2018

Last Updated

October 30, 2017

Record last verified: 2017-10

Locations